Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance

BACKGROUND: Colorectal carcinoma (CRC) is the third most common cancer worldwide. Platinum-based anticancer compounds still constitute one mainstay of systemic CRC treatment despite limitations due to adverse effects and resistance development. Trabectedin has shown promising antitumor effects in CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Englinger, B, Mair, M, Miklos, W, Pirker, C, Mohr, T, van Schoonhoven, S, Lötsch, D, Körner, W, Ferk, F, Knasmüller, S, Heffeter, P, Keppler, B K, Grusch, M, Berger, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318979/
https://www.ncbi.nlm.nih.gov/pubmed/28095394
http://dx.doi.org/10.1038/bjc.2016.449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318979/
https://www.ncbi.nlm.nih.gov/pubmed/28095394
http://dx.doi.org/10.1038/bjc.2016.449

Ejemplares similares